Skip to content

Abstract 11768: Association Between Clinical Events and Subsequent Events Among Anticoagulant Treated Patients with Atrial Fibrillation: Real World Data Analyses in US and UK

Nov 2026 · Circulation · 0 citations

Abstract

Background: Oral anticoagulants (OACs) reduce the risk of thromboembolic events in atrial fibrillation (AF) patients; but thrombotic and bleeding events still occur. More evidence is needed on how prior events affect future event risk and mortality. Research Question: To quantify associations between the first occurrence of clinical events of interest, “prior” clinical events, defined as ischemic stroke/systemic embolism (IS/SE), major bleed (MB), intracranial hemorrhage (ICH), myocardial infarction (MI) and the risk of subsequent clinical events (IS/SE, MB, ICH, MI, cardiovascular (CV) and all-cause mortality) among OAC-treated AF patients. Methods: Adults with newly diagnosed AF initiating an OAC within 90 days of AF diagnosis were included from the UK Clinical Practice Research Datalink linked to Hospital Episode Statistics and US Medicare claims (2012-2021), separately. Patients were tracked from their first OAC prescription after AF diagnosis until death or end of data. The first clinical event of interest was required to occur on treatment. Subsequent non-fatal IS/SE, MB, ICH and MI were analyzed using Andersen-Gill gap-time models; CV and all-cause mortality were analyzed using Cox regression. Results: The study included 70,887 UK and 314,818 US patients (mean age 77 years; 53% male). In the UK cohort, 70.1% initiated direct OACs and 29.9% initiated vitamin K antagonists; corresponding proportions in the US cohort were 74.3% and 25.7%. Prior events substantially increased the risk of recurrence of the same event: in the UK, each prior IS/SE increased the risk of subsequent IS/SE by 153% (HR 2.5, 95% CI 2.3-2.8); each prior MB increased risk of subsequent MB by 89% (HR 1.9, 95% CI 1.8-1.9); and each prior MI increased risk of subsequent MI by 260% (HR 3.6, 95% CI 3.1-4.2); corresponding estimates from the US cohort were 150%, 93% and 144% (Table 1). Additionally, prior MB events were associated with 33-41% increased risk of subsequent IS/SE in both UK and US cohorts. Finally, prior clinical events were associated with substantially higher all-cause mortality, ranging from a 51% to 161% increase depending on event type and cohort (Table 1). Conclusions: In contemporary OAC-treated AF populations, the occurrence of thrombotic or bleeding events was associated with a marked increase in the risk of recurrent events and all-cause mortality. These findings underscore the importance of continuous risk reassessment and highlight the substantial risk of clinical events that persist despite current anticoagulant therapy.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.